News

Dr. Agarwal’s Health Care Limited announced that the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited has become effective from November 1, 2026, with an Appointed Date of April 1, 2026, following the filing of the National Company Law Tribunal order with the Registrar of Companies in Chennai on October 15, 2026. The board also approved the reclassification of Dr. Agarwal’s Eye Hospital Limited’s authorized share capital of 20,00,00,000 Equity Shares of Rs 1 face value and its subsequent combination with Dr. Agarwal’s Health Care Limited’s authorized share capital, increasing the latter’s total authorized capital to Rs 110 crore. Additionally, November 18, 2026, has been fixed as the Record Date for allotment of consideration shares to eligible shareholders of Dr. Agarwal’s Eye Hospital Limited, with a share exchange ratio of 23 shares of Dr. Agarwal’s Health Care Limited for every 2 shares of Dr. Agarwal’s Eye Hospital Limited.

Dr. Agarwal’s Health Care Limited announced that the Scheme of Amalgamation between Dr. Agarwal’s Eye Hospital Limited and Dr. Agarwal’s Health Care Limited has become effective from November 1, 2026, with an Appointed Date of April 1, 2026, following the filing of the National Company Law Tribunal order with the Registrar of Companies in Chennai on October 15, 2026. The board also approved the reclassification of Dr. Agarwal’s Eye Hospital Limited’s authorized share capital of 20,00,00,000 Equity Shares of Rs 1 face value and its subsequent combination with Dr. Agarwal’s Health Care Limited’s authorized share capital, increasing the latter’s total authorized capital to Rs 110 crore. Additionally, November 18, 2026, has been set as the Record Date for allotment of consideration shares to eligible shareholders of Dr. Agarwal’s Eye Hospital Limited, with a share exchange ratio of 23 shares of Dr. Agarwal’s Health Care Limited for every 2 shares of Dr. Agarwal’s Eye Hospital Limited.

Dr. Agarwal’s Health Care Limited submitted a certificate to the BSE Limited and National Stock Exchange of India Limited on October 7, 2026, confirming the details of securities dematerialized and rematerialized for the quarter ended September 30, 2026, as per Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018, with KFin Technologies Limited acting as the Registrar and Share Transfer Agent.

Dr. Agarwal’s Health Care Limited announced on Tuesday, September 29, 2026, that Orbit Healthcare Services Nigeria Ltd. has become a wholly owned subsidiary of Orbit Mauritius, a direct wholly owned subsidiary of Dr. Agarwal’s Health Care Limited, following an intimation received from Orbit Mauritius.

Dr. Agarwal’s Health Care Limited announced that Sanjay Anand will cease to be an Independent Director of the company upon completion of his five-year term at the close of business hours on September 29, 2026, in accordance with the Companies Act, 2013 and SEBI Listing Regulations. The company expressed appreciation for Anand’s contributions and disclosed revised committee compositions following his departure, including changes to the Audit Committee, Nomination & Remuneration Committee, Stakeholders Relationship Committee, Corporate Social Responsibility Committee, and Risk Management Committee.